Statins for secondary stroke prevention in patients without known coronary heart disease: The Jury is still out

Cerebrovascular Diseases

Volumn 18, Issue 1, 2004, Pages 1-2

  Goldstein, Larry B ^a   Amarenco, Pierre ^b   Bogousslavsky, Julien ^c   Callahan, Alfred S ^d   Hennerici, Michael G ^e   Welch, K Michael A ^f   Zivin, Justin ^g   Sillesen, Henrik ^h  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HÔPITAL LARIBOISIÈRE   (France)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d Neurologic Consultants PC   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; EDITORIAL; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; STROKE; TREATMENT OUTCOME;

CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 2142683621     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078600     Document Type: Editorial

References (8)

1. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
2. LIPID Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The longterm Intervention with Pavastatin in Ischaemic Disease (LIPID) study group. N Engl J Med 1998;339:1349-1357.
3. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moye LA, Piller LB, Rutherford J, Simpson LM, Braunwald E: Reduction of stroke incidence after myocardial infarction with pravastatin. The Cholesterol and Recurrent Events (CARE) Study. Circulation 1999;99:216-223.
4. Heart Protection Collaborative Study Group: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
5. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002;360:1623-1630.
6. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-1158.
7. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
8. The SPARCL Investigators: Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Cerebrovasc Dis 2003;16:389-395.